Related Experiment Videos
Insights
Urokinase effectively restores patency in occluded hemodialysis catheters, improving outcomes. This thrombolytic agent safely extends catheter usability for patients requiring dialysis.
Area of Science:
- Nephrology
- Vascular Access Management
Background:
- Hemodialysis patients with double lumen catheters face risks of catheter occlusion.
- Catheter occlusion can disrupt treatment and necessitate catheter replacement.
Purpose of the Study:
- To evaluate the clinical outcomes and cost-effectiveness of urokinase for declotting hemodialysis catheters.
- To assess the safety and efficacy of urokinase in restoring catheter patency.
Main Methods:
- A 2-year study evaluated urokinase use in hemodialysis patients with occluded double lumen catheters.
- Data collected on patency restoration and clinical outcomes.
Main Results:
- Urokinase successfully restored patency in 95 out of 102 (93.1%) occluded catheters.
- The treatment demonstrated safety and effectiveness in declotting procedures.
Conclusions:
- Urokinase is a safe and effective agent for restoring patency in occluded hemodialysis catheters.
- Restoring catheter patency with urokinase can extend the functional lifespan of dialysis catheters.
Abstract:
All hemodialysis patients with temporary or permanent double lumen catheters are at risk for catheter occlusion. Clinical outcomes and cost-effectiveness of using urokinase, a thrombolytic agent, to declot occluded double lumen dialysis catheters were evaluated for 2 years. Patency was restored in 95 of 102 catheters. These data support the use of urokinase to safely and effectively restore patency, thereby extending the length of time a catheter can be used for dialysis.